Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
Autori principali: | Xue, L, Hardman, C, Chen, W, Batty, P, Ogg, G, Erpenbeck, V, Sandham, D |
---|---|
Natura: | Conference item |
Pubblicazione: |
American Thoracic Society
2018
|
Documenti analoghi
Documenti analoghi
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
di: Chen, W, et al.
Pubblicazione: (2018) -
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
di: Sandham, D, et al.
Pubblicazione: (2019) -
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
di: Hardman, C, et al.
Pubblicazione: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
di: Xue, L, et al.
Pubblicazione: (2019) -
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma
di: Veit J. Erpenbeck, et al.
Pubblicazione: (2016-12-01)